Nasdaq · CIK 0001770121
SANA Sana Biotechnology, Inc.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $2.79 on Oct 9, 2026, +4% from the 52-week low and -53% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
SANAOct 9, 2026 · close 2.79
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Sana Biotechnology, Inc., scored.
Transactions
The last 27 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Hans Edgar Bishop director | AGrant or award Common Stock | +8,680 | $0.00 | $0 | 5,863,480 | 6 d ago |
| Jul 7, 2025 | Hans Edgar Bishop director | AGrant or award Common Stock | +7,842 | $0.00 | $0 | 5,828,955 | Jul 8, 2025 |
| Jun 5, 2025 | Joshua H. Bilenker director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Hans Edgar Bishop director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Richard Mulligan director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Robert Nelsen director, owner | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Alise Reicin director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Robert L. Rosiello director | AGrant or award Stock Option (Right to Buy)derivative | +115,000 | $0.00 | $0 | 115,000 | Jun 9, 2025 |
| Jun 5, 2025 | Patrick Y Yang director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Mary Agnes Wilderotter director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Jun 5, 2025 | Michelle Seitz director | AGrant or award Stock Option (Right to Buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jun 9, 2025 |
| Apr 7, 2025 | Hans Edgar Bishop director | AGrant or award Common Stock | +16,339 | $0.00 | $0 | 5,821,113 | Apr 8, 2025 |
| Mar 7, 2025 | Steve Harr President & CEO | MOption exercise Common Stock | +50,000 | $0.00 | $0 | 7,889,750 | Mar 10, 2025 |
| Mar 7, 2025 | Bernard J Cassidy EVP & General Counsel | MOption exercise Common Stock | +11,041 | $0.00 | $0 | 115,823 | Mar 10, 2025 |
| Mar 10, 2025 | Steve Harr President & CEO | FTax withholding Common Stock | -12,820 | $2.56 | $33k | 7,876,930 | Mar 10, 2025 |
| Mar 10, 2025 | Bernard J Cassidy EVP & General Counsel | FTax withholding Common Stock | -2,833 | $2.56 | $7,252 | 112,990 | Mar 10, 2025 |
| Mar 6, 2025 | Bernard J Cassidy EVP & General Counsel | AGrant or award Restricted Stock Unitsderivative | +53,333 | $0.00 | $0 | 53,333 | Mar 10, 2025 |
| Mar 6, 2025 | Bernard J Cassidy EVP & General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Mar 10, 2025 |
| Mar 7, 2025 | Bernard J Cassidy EVP & General Counsel | MOption exercise Restricted Stock Unitsderivative | -11,041 | $0.00 | $0 | 33,126 | Mar 10, 2025 |
| Mar 6, 2025 | Steve Harr President & CEO | AGrant or award Restricted Stock Unitsderivative | +166,667 | $0.00 | $0 | 166,667 | Mar 10, 2025 |
| Mar 6, 2025 | Steve Harr President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Mar 10, 2025 |
| Mar 7, 2025 | Steve Harr President & CEO | MOption exercise Restricted Stock Unitsderivative | -50,000 | $0.00 | $0 | 150,000 | Mar 10, 2025 |
| Jan 8, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VI LP | -100,000 | $6.11 | $611k | 4,732,423 | Jan 10, 2025 |
| Jan 8, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VI LP | -25,000 | $6.50 | $163k | 4,707,423 | Jan 10, 2025 |
| Jan 8, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VI LP | -164,912 | $6.71 | $1.1M | 4,542,511 | Jan 10, 2025 |
| Jan 8, 2025 | Fmr LLC owner, other | SOpen-market sale Common Stockindirect: F-Prime Capital Partners Life Sciences Fund VI LP | -1,000 | $7.26 | $7,260 | 4,541,511 | Jan 10, 2025 |
| Jan 6, 2025 | Hans Edgar Bishop director | AGrant or award Common Stock | +14,285 | $0.00 | $0 | 5,804,774 | Jan 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Joshua H. Bilenkerdirector
- Hans Edgar Bishopdirector
- Bernard J CassidyEVP & General Counsel
- Fmr LLCowner, other
- Steve HarrPresident & CEO
- Richard Mulligandirector
- Robert Nelsenowner, director
- Alise Reicinceo, officer, director
- Robert L. Rosiellodirector
- Michelle Seitzdirector
- Mary Agnes Wilderotterdirector
- Patrick Y Yangdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.